Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.

被引：1
|
作者：
Calegari, Maria Alessandra
Orlandi, Armando
Indellicati, Giulia
Martini, Maurizio
Cocomazzi, Alessandra
Bagala, Cinzia
Zurlo, Valeria
Di Dio, Carmela
Barile, Rosalba
Monterisi, Santa
Cassano, Alessandra
Astone, Antonio
Barone, Carlo
机构：
[1] Policlin Univ A Gemelli, UOC Oncol Med, Rome, Italy
[2] Policlin Univ A Gemelli, Ist Anat Patol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15295
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma
    Thoma C.
    Nature Reviews Gastroenterology & Hepatology, 2019, 16 (3) : 140 - 140
  • [22] Modified FOLFIRINOX (mFOLFIRINOX) as second-line chemotherapy in pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Higgs, Domenic
    James, Alex
    Van Gemert, Tegan
    James, Alena Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] RAS mutations and their correlation with survival of patients with advanced pancreatic adenocarcinoma.
    Almeida, Thiago Lins
    Gomes, Jessica Ribeiro
    Cesar Machado, Marcel Cerqueira
    Buzaid, Antonio C.
    Maluf, Fernando C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [24] PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma.
    Rivera, Fernando
    Gallego, Javier
    Guillen, Carmen
    Benavides, Manuel
    Lopez-Martin, Jose A.
    Betticher, Daniel C.
    Kueng, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer REPLY
    Conroy, Thierry
    Gourgou-Bourgade, Sophie
    Ducreux, Michel
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08): : 769 - 769
  • [26] Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
    Baretti, Marina
    Durham, Jennifer N.
    Walker, Rosalind
    Mitcheltree, Amber-Lynn
    Christmas, Brian
    Cope, Leslie
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Operated Pancreatic Cancer: Modified FOLFIRINOX versus Gemcitabine
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (03): : 290 - 290
  • [28] Folfirinage: Tolerance and efficacy of folfirinox in elderly patients with advanced pancreatic adenocarcinoma
    Baldini, C.
    Escande, A.
    Bouche, O.
    Bourgeois, V.
    Renaut-Vantroys, T.
    Ploquin, A.
    Desauw, C.
    Hebbar, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S196 - S196
  • [29] A triple approach strategy for patients with locally advanced pancreatic adenocarcinoma.
    Cantore, M.
    Girelli, R.
    Mambrini, A.
    Frigerio, I.
    Boz, G.
    Simoncini, E.
    Lusenti, A.
    Orlandi, M.
    Bassi, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma
    Raponi, Mitch
    Isaacson, Jeff
    Hahn, Hejin
    Bartosiewicz, Mike
    Magnusson, Andrea
    Lin, Kevin
    Rolfe, Lindsey
    Allen, Andrew
    Picozzi, Vincent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S84 - S85
12345